EN DE
Watch AbbVie Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AbbVie Inc (ABBV) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of AbbVie Inc stock $260, price $288, that is 9.9% below the price, quality 75 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AI AbbVie Inc logo Some data Nov 6, 2026

AbbVie Inc

ABBV · US
Strong quality, but expensive

Our calculation puts a fair price 10% below what the stock costs today.

Quality 75/100
Solidly profitable · 15.7% net margin (TTM)
Generates free cash flow
0.6% dividend yield · Well covered
Wide moat 74/100
Mixed Growth (revenue 5y +6.0 %/yr in USD)
Negative equity (buybacks among others)
Mixed vs. peers (6/12)
Neutral coverage
Insiders sold $8.2M (6M)
Some data
Fair value $259.62 · Overvalued (−9.9%)
Quality growth

Risks from the AI analysis

🚩Biosimilar rivals eroding key biologics🚩Medicare price negotiations on Botox🚩Revenue concentration in two products
Watch AbbVie Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$294.89 $88.56 Fair Value $259.62 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $88.56 – $294.89 · fair‑value band $168.34 – $358.82 · the $288.24 price screens above the $259.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow AbbVie in your weekly email

Every Wednesday you see whether AbbVie is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Show moreShow less

The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.

In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.

Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.

The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Stock analysis

AbbVie Inc (ABBV) currently trades at $288.24, while our model-based Fair Value estimate is $259.62, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $133.96 per share, and 0 of the 23 models we run sit above the $288.24 price.

Bear case: the Growth Earnings group reads lowest at $40.80, and 23 of the 23 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $168.34 (bear) to $358.82 (bull), the price of $288.24 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AbbVie Inc reported revenue of $61.2B in FY2025 versus $56.2B in FY2021, a compound +2.1%/yr. Reported net income was $4.2B in FY2025, compounding −22.2%/yr from FY2021.

Key figures

Market cap $510B Mega · P/E ratio 49.5 · P/S ratio 7.73 · EPS (TTM) $5.82 · Dividend yield 0.6% · Net margin 15.7% · Return on equity 62.3% · Return on assets (EBIT) 11.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 2% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −10%, ABBV screens cheaper than that median.

Fair Value models

Bear $168.34 Fair Value $259.62 Bull $358.82
Price $288.24 · Downside -9.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.47 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $132.38 $264.77 $515.82 76
EPV $79.37 $100.93 $120.71 74
5Y EBITDA Exit $125.50 $236.97 $371.84 73
All 23 models by family
DCF Models
FCF DCF $132.38 $264.77 $515.82 76
Owner Earnings $60.24 $133.96 $273.74 71
5Y Revenue Exit $67.85 $123.60 $195.39 71
5Y EBITDA Exit $125.50 $236.97 $371.84 73
5Y P/E Exit $43.21 $75.14 $108.64 70
10Y Revenue Exit $84.17 $144.08 $227.55 65
10Y EBITDA Exit $126.71 $230.19 $377.84 66
10Y P/E Exit $69.79 $107.28 $153.67 64
Earnings-Based
Graham-Dodd $16.26 $62.99 $85.42 64
Lynch FV $15.43 $22.05 $28.66 61
PEG = 1.0 $15.43 $22.05 $28.66 57
EPV $79.37 $100.93 $120.71 74
Dividend Discount
Gordon GGM $69.12 $167.36 $326.94 64
DDM Multi-Stage $69.12 $128.61 $171.55 66
Multiples
P/E Multiple $39.46 $52.61 $65.77 63
P/S Multiple $30.49 $40.65 $50.82 58
EV/EBIT $108.83 $157.15 $205.47 65
EV/EBITDA $131.61 $187.53 $243.44 67
EV/Revenue $36.56 $67.70 $98.85 52
Growth DCF
Growth DCF $135.02 $269.98 $540.60 73
Rev-Margin DCF $67.85 $124.05 $193.13 71
Economic Profit
ROIC Compounder $90.48 $129.81 $179.41 71
Growth Earnings
Growth-Adj P/E $28.56 $40.80 $53.04 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 75/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 99
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 88
How calm the share price moves, does not count
Price momentum 77
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 84
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $8.2M and none bought.

  • SaleNicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICER32,710 shares at $250.00$8.2MAug 14, 2026
  • SaleDavid Ryan PurdueSVP, Controller5,230 shares at $233.56$1.2MMar 4, 2026
  • SalePerry C SiatisEVP, GC AND SECRETARY2× since Feb 25, 2026: 41,049 shares, avg. $232.00$9.5MMar 2, 202610b5-1 plan

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Start year 2020 (pandemic). Over 10 years: +10.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.1%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.8% vs −2.7%, slowing
Profit margin 2018 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 16%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.4% a year for the price and +5.6% for the forecasts.
Forecast 2026 (sales)+10.8%
Forecast 2027 (sales)+8.8%
Projected 2028 (sales)+7.9%
Projected 2029 (sales)+7.1%
Projected 2030 (sales)+6.2%

ABBV screens overvalued: fair value 10% below the price. Compare with Eli Lilly and Company →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Note from the team Nov 5, 2026
AI conclusion: Pharma scale and immunology portfolio growth provide durability through high gross margins, yet high leverage and thin net margins limit overall resilience.
Main risk: Biosimilar versions from companies such as Amgen or Sandoz could take market share from AbbVie's Skyrizi and Rinvoq after their patents expire, pressuring prices and margins in the immunology portfolio.
Bull case: AbbVie could accelerate its pipeline through AI partnerships and further acquisitions to launch differentiated successors before major patent expiries hit Skyrizi and Rinvoq.
Bear case: If biosimilar competition and Medicare pricing pressures intensify without sufficient new launches, AbbVie could see sustained revenue declines across its core immunology and aesthetics franchises.
AbbVie’s immunology portfolio, led by Skyrizi and Rinvoq, delivered strong double-digit growth in the third quarter and supported a raised full-year outlook as Humira continues to fade. The recent Apogee acquisition adds further depth to that pipeline. Our models still see the shares as overvalued. Will the newer products sustain enough momentum to close the gap or will other pressures keep the premium in check?
Join the discussion →

Compare AbbVie Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 75 · Top 25%
Fair Value upside −9.9% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 3.2% · Below median
Net margin (12 months) 15.7% · Above median
Operating margin (12 months) 37.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 10.3% · Above median
Dividend yield (12 months) 0.6% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 49.5× · Priciest 25%
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 7.73× · Priciest 25%
Price / free cash flow (fiscal year) 28.7× · Pricier than median
EV/EBITDA 17.4× · Pricier than median
PEG 0.60× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 20
FUTURE (revenue growth)52 · sector 34
PAST (return on equity)0 · sector 41
HEALTH (low debt)0 · sector 93
DIVIDEND (yield)12 · sector 38

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sanofi SNY $46.91 $70.49 +50% vs ABBV
Bristol-Myers Squibb Company BMY $63.13 $75.91 +20% vs ABBV
Gilead Sciences, Inc GILD $167.57 $191.93 +15% vs ABBV
Amgen Inc AMGN $460.28 $507.39 +10% vs ABBV
Novartis AG NOVN CHF 134.12 CHF 119.58 −11% vs ABBV
Merck & Co MRK $146.94 $129.26 −12% vs ABBV
Pfizer Inc PFE $29.88 $24.87 −17% vs ABBV
Roche Holding RO CHF 399.00 CHF 326.56 −18% vs ABBV
Johnson & Johnson, JNJ $272.32 $168.85 −38% vs ABBV
Eli Lilly and Company LLY $1,365 $749.92 −45% vs ABBV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AbbVie Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AbbVie Inc Fair Value". https://www.fairvalue-calculator.com/stock/ABBV

Frequently asked questions

Is AbbVie Inc (ABBV) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $259.62 versus a price of $288.24, about 10% lower (overvalued).
What is the fair value of ABBV?
Our model-based fair value for AbbVie Inc is $259.62 (as of Nov 6, 2026), built from audited fundamentals. The current price: $288.24.
What is the quality score of ABBV?
AbbVie Inc has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AbbVie Inc (ABBV)?
Our model-based price target is the fair value of $259.62 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $168.34, optimistic scenario $358.82. It is a calculation from audited fundamentals, not an analyst target.
What is the AbbVie Inc stock forecast for 2026?
Our models put fair value at $259.62, about 10% lower versus a price of $288.24 (overvalued). Cautious scenario $168.34, optimistic scenario $358.82. The calculation is refreshed regularly with new filings.
What is the revenue of AbbVie Inc (ABBV)?
AbbVie Inc reported trailing-twelve-month revenue of about $66.0B (latest available figure, as of Nov 6, 2026).
Does AbbVie Inc pay a dividend?
AbbVie Inc currently shows a dividend yield of 0.60% relative to its recent price (as of Nov 6, 2026).
What growth is priced into AbbVie Inc (ABBV)?
For today's price to be fair in a discounted-cash-flow model, AbbVie Inc would have to grow free cash flow by +12.0 % per year for five years (discount rate 7.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ABBV use?
Our models discount AbbVie Inc at 7.6 %: a base by market capitalisation (mega), damped by beta 0.23, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AbbVie Inc that is +12.0 % per year a year over ten years, using the same discount rate (7.6 %) and the same formula as our fair value.
How much growth has AbbVie Inc (ABBV) delivered so far?
Over the past 5 years revenue at AbbVie Inc grew +6.0 % a year. The price currently implies +12.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AbbVie Inc (ABBV) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into AbbVie Inc (+12.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AbbVie Inc (ABBV)?
The free-cash-flow yield on the price is 3.49 %: that much free cash flow AbbVie Inc produces per unit of market value. When it exceeds the discount rate of our models (7.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AbbVie Inc (ABBV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AbbVie Inc it is $259.62 per share (as of Nov 6, 2026), against a price of $288.24. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is AbbVie Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ABBV trades above its calculated fair value: price $288.24, fair value $259.62, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABBV?
No. The price is what the market pays today ($288.24); the fair value is what the company's own numbers justify ($259.62). For AbbVie Inc the two are $28.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is AbbVie Inc worth?
The market values AbbVie Inc at about $510B (market capitalisation, as of Nov 6, 2026). Per share that is $288.24; our models calculate a fair value of $259.62 per share.
What do the bullish and bearish scenarios say about ABBV?
Our models span a range for AbbVie Inc: cautious scenario $168.34, base $259.62, optimistic $358.82 per share (as of Nov 6, 2026, price $288.24). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ABBV?
AbbVie Inc trades at a price-to-earnings ratio of 49.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $259.62 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 79.2 (reported for FY2025: 121.1). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 7 of the years ex one-offs: 25.4. Other multiples: PEG 0.6, P/S 7.7, EV/EBITDA 17.4.
What is the PEG ratio of ABBV?
The PEG ratio of AbbVie Inc is 0.60 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of AbbVie Inc (ABBV)?
Balance-sheet figures for AbbVie Inc (as of Nov 6, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is ABBV from its 52-week high?
AbbVie Inc trades at $288.24, about 2% below its 52-week high of $294.89 and 47% above the low of $195.99 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $259.62 is for.
Which stocks are comparable to AbbVie Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, Roche Holding, Merck & Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AbbVie Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $288.24, calculated fair value $259.62 (−10%), Quality Score 75/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABBV calculated?
We run AbbVie Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $259.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. AbbVie Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AbbVie Inc (ABBV)?
The closing price on Nov 5, 2026 was $288.24. Our model-based fair value is $259.62, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AbbVie Inc right now?
A fairly wide model range ($168.34 to $358.82) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of AbbVie Inc (ABBV) come from?
Earnings per share at AbbVie Inc grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.7 %, EBIT margin −2.1 %, tax rate +0.7 %, residual (interest, one-offs) −8.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of AbbVie Inc

How large is the market capitalisation of AbbVie Inc (ABBV)?
The market capitalisation of AbbVie Inc is $510B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AbbVie Inc (ABBV)?
The price-to-sales ratio of AbbVie Inc is 7.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AbbVie Inc (ABBV)?
Earnings per share at AbbVie Inc are $5.82 (price ÷ EPS = P/E 49.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AbbVie Inc (ABBV)?
The dividend yield of AbbVie Inc is 0.6% (payout 19.4%, on adjusted earnings, reported 29.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AbbVie Inc (ABBV)?
The net margin of AbbVie Inc is 15.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AbbVie Inc (ABBV)?
The return on equity (ROE) of AbbVie Inc is 62.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AbbVie Inc (ABBV)?
On an EBIT basis the return on assets of AbbVie Inc is 11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AbbVie Inc (ABBV)?
The operating margin of AbbVie Inc is 37.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AbbVie Inc (ABBV)?
Revenue at AbbVie Inc is growing +10.3% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AbbVie Inc (ABBV)?
Earnings per share at AbbVie Inc are growing +22.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does AbbVie Inc (ABBV) carry?
The net debt of AbbVie Inc is $63.8B (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch AbbVie Inc in the live analysis

One click puts AbbVie Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.